| Region: | |
| Category: |
(59 reports matching your criteria)
|
Infectious Diseases in Europe: Market Segment Forecasts and Supplier Shares
5/20/2013 | published by: Venture Planning Group
... companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies. The report provides market segmentation analysis of over 70 diseases and viruses ...
|
read more...
|
$19,700.00
|
|
PharmaPoint: Chronic Myeloid Leukemia (CML) - Italy Drug Forecast and Market Analysis to 2022
4/30/2013 | published by: GlobalData
... to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Chronic Myeloid Leukemia (CML) - Germany Drug Forecast and Market Analysis to 2022
4/30/2013 | published by: GlobalData
... to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Chronic Myeloid Leukemia (CML) - Spain Drug Forecast and Market Analysis to 2022
4/30/2013 | published by: GlobalData
... to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and Market Analysis to 2022
4/30/2013 | published by: GlobalData
... to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022
4/30/2013 | published by: GlobalData
... Market Analysis to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022
3/31/2013 | published by: GlobalData
... (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Multiple Sclerosis - Italy Drug Forecast and Market Analysis to 2022
3/31/2013 | published by: GlobalData
... sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022
3/31/2013 | published by: GlobalData
... Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 2022
3/31/2013 | published by: GlobalData
... (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Multiple Sclerosis - Spain Drug Forecast and Market Analysis to 2022
3/31/2013 | published by: GlobalData
... (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying ...
|
read more...
|
$4,995.00
|
|
Medical & Scientific Research (European) - Industry Report
3/18/2013 | published by: Plimsoll Publishing Ltd.
... & DEVELOPPEMENT, NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO and CBMM EUROPE B.V.. This report includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Medical & Scientific Research ...
|
read more...
|
$1,200.00
|
|
Bioscience (UK) - Industry Report
3/18/2013 | published by: Plimsoll Publishing Ltd.
... LTD. This report covers activities such as research, science, pharmaceutical, antibodies, biologics and includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Bioscience analysis is ideal for ...
|
read more...
|
$525.00
|
|
Clinical Research (UK) - Industry Report
3/18/2013 | published by: Plimsoll Publishing Ltd.
... QUOTIENT CLINICAL LTD. This report covers activities such as clinical trials, cro, biotechnology, clinical research, pharmaceutical development and includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest ...
|
read more...
|
$525.00
|
|
Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 2022
3/1/2013 | published by: GlobalData
... (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying ...
|
read more...
|
$4,995.00
|
|
Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022
3/1/2013 | published by: GlobalData
... (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying ...
|
read more...
|
$4,995.00
|
|
Multiple Sclerosis - Italy Drug Forecast and Market Analysis to 2022
3/1/2013 | published by: GlobalData
... sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with ...
|
read more...
|
$4,995.00
|
|
Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022
3/1/2013 | published by: GlobalData
... Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Epilepsy - Italy Drug Forecast and Market Analysis to 2022
2/15/2013 | published by: GlobalData
... characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Epilepsy - Spain Drug Forecast and Market Analysis to 2022
2/15/2013 | published by: GlobalData
... characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022
2/15/2013 | published by: GlobalData
... characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Epilepsy - France Drug Forecast and Market Analysis to 2022
2/15/2013 | published by: GlobalData
... characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Epilepsy - Germany Drug Forecast and Market Analysis to 2022
2/15/2013 | published by: GlobalData
... characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: HIV - France Drug Forecast and Market Analysis to 2022
1/31/2013 | published by: GlobalData
... causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: HIV - Germany Drug Forecast and Market Analysis to 2022
1/31/2013 | published by: GlobalData
... causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for ...
|
read more...
|
$4,995.00
|
